Results 311 to 320 of about 292,383 (379)

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial. Methods A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational ...
Stefano Di Donato   +9 more
wiley   +1 more source

Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes. [PDF]

open access: yesGraefes Arch Clin Exp Ophthalmol
Baytaroğlu İMU   +3 more
europepmc   +1 more source

Genome‐Wide Aggregated Trans Effects Analysis Identifies Genes Encoding Immune Checkpoints as Core Genes for Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The sparse effector “omnigenic” hypothesis postulates that the polygenic effects of common single nucleotide polymorphisms (SNPs) on a typical complex trait are mediated by trans effects that coalesce on expression of a relatively sparse set of core genes.
Athina Spiliopoulou   +9 more
wiley   +1 more source

COVID-19 vaccination rates and factors affecting vaccination in children with rheumatic disease. [PDF]

open access: yesArch Rheumatol
Aydın T   +13 more
europepmc   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic ...
Austin M. Wheeler   +18 more
wiley   +1 more source

Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease. [PDF]

open access: yesPLoS One
d'Alessandro M   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy